Covista Inc. (CVSA) SEC Filings & Earnings Calls
EquiReason read 16 Covista Inc. SEC filings in the last 12 months. Latest: DEF 14A on 2026-10-02 — Proxy statement disclosing executive compensation, a new equity incentive plan, and detailed non-GAAP financial metrics..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 4.5B
- P/E TTM
- 18.8
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
2 Oct 2026DEF 14AProxy statement disclosing executive compensation, a new equity incentive plan, and detailed non-GAAP financial metrics.open
Figures in the filing · each found in the filing text
| Revenue · FY2026 | $1.95B | +9% y/y |
| Net Income · FY2026 | $252M | +6% y/y |
| Adjusted EBITDA · FY2026 | $522M | +13% y/y |
| Adjusted EBITDA Margin · FY2026 | 26.7% | |
| Free Cash Flow · FY2026 | $393M | +39% y/y |
| Net Debt · FY2026 | $267M | |
| Net Leverage · FY2026 | $0.50 | |
| Adjusted Net Income · FY2026 | $295M | +15% y/y |
| Diluted Earnings Per Share · FY2026 | $7.04 | +14% y/y |
| Adjusted Diluted Earnings Per Share · FY2026 | $8.25 | +24% y/y |
Risks flagged
Restructuring and strategic advisory costs
“Restructuring expense $6,329 (thousands) and strategic advisory costs $18,562 (thousands) for FY26.”
23 Sep 20268-K · 1.01, 2.03Covista amended credit agreement to reprice all $510M outstanding term loans, reducing interest rate from SOFR+2.25% to SOFR+2.00%.open
Risks flagged
Soft call provision may limit future refinancing flexibility for six months.
“The repriced term loans are subject to a 1.00% premium on certain prepayments, repricings or amendments constituting a Repricing Transaction occurring on or prior to the date that is six months after the Effective Date.”
6 Aug 20268-K · 2.02Covista reports FY2026 results: revenue $1.954B (+9.3% YoY), adjusted EPS $8.25 (+23.7% YoY), total enrollment +8.4% in Q4; initiates FY2027 guidance with revenue $2.05-2.09B and adjusted EPS $8.90-9.15.earningsopen
Figures in the filing · each found in the filing text
| Revenue · FY2026 | $1.95B | +9% y/y |
| Revenue · Q4-2026 | $501M | +10% y/y |
| Total student enrollment · Q4-2026 | 99,472 | +8% y/y |
| GAAP diluted EPS · FY2026 | $7.04 | |
| Adjusted EPS · FY2026 | $8.25 | +24% y/y |
| Adjusted EBITDA · FY2026 | $522M | +14% y/y |
| Adjusted EBITDA margin · FY2026 | 26.7% | |
| GAAP net income · FY2026 | $252M | +6% y/y |
| Adjusted net income · FY2026 | $295M | +15% y/y |
| Operating income · FY2026 | $383M | +12% y/y |
Guidance
FY27 revenue $2.05-2.09B (5-7% growth); FY27 adjusted EPS $8.90-9.15 (8-11% growth)
Initiated FY2027 guidance with revenue growth 5-7% and adjusted EPS growth 8-11%; management cites enhanced momentum and tracking ahead of long-term targets.
Risks flagged
Dependence on enrollment growth sustainability; regulatory approval for new programs.
“Walden began enrolling students in four new programs and submitted two additional behavioral health programs for regulatory approval.” · word for word
Healthcare workforce shortage could impact demand if economic conditions change.
“help close the healthcare workforce shortage the country urgently needs solved” · word for word
6 Aug 202610-KCovista Inc. filed its annual report (10-K) for FY2026, providing comprehensive business and regulatory overview.open
Figures in the filing · each found in the filing text
| Enrollment (students) · FY2026 | 100,000 | |
| 90/10 rate - Chamberlain University · Chamberlain · FY2025 | 70.0% | |
| 90/10 rate - Walden University · Walden · FY2025 | 82.0% | |
| 90/10 rate - AUC · Medical and Veterinary · FY2025 | 86.0% | |
| 90/10 rate - RUSM · Medical and Veterinary · FY2025 | 86.0% | |
| 90/10 rate - RUSVM · Medical and Veterinary · FY2025 | 77.0% | |
| Consolidated 90/10 rate · FY2025 | 78.0% | |
| Surety bonds posted · FY2026 | $80M |
Risks flagged
Regulatory risk - 90/10 Rule
“Under this regulation, an institution that derives more than 90% of its revenue on a cash basis from Federal education assistance funds in two consecutive fiscal years loses eligibility to participate in Title IV programs.” · word for word
Regulatory risk - Borrower Defense to Repayment
“These changes would increase financial liability risk and reputational risk for Covista.” · word for word
Regulatory risk - Change of Ownership
“If regulators do not approve, or delay their approval, of transactions involving a material change of ownership or change of control of Covista, the eligibility of our institutions to participate in Title IV programs, our institutions’ accreditation and our institutions’ state licenses may be impaired in a manner that materially and adversely affects our bus”
Cohort default rate increase risk
“As repayment activity resumes, cohort default rates may increase from these historically low levels.” · word for word
7 May 20268-K · 2.02Total student enrollment 100,585 (+7% y/y); Revenue $487M (+4% y/y); GAAP net income $42M; Guidance: Revenue guidance raised from $1,900M-$1,940M to $1,930M-$1,945M; adj. EPS from $7.80-$8.00 to $7.95-$8.15earningsopen
Figures in the filing · each found in the filing text
| Total student enrollment · total · Q3-2026 | 100,585 | +7% y/y |
| Revenue · total · Q3-2026 | $487M | +5% y/y |
| GAAP net income · total · Q3-2026 | $42M | |
| Adjusted EBITDA · total · Q3-2026 | $128M | +0% y/y |
| Adjusted EBITDA margin · total · Q3-2026 | 26.3% | |
| Diluted earnings per share · total · Q3-2026 | $1.20 | -25% y/y |
| Adjusted earnings per share · total · Q3-2026 | $1.98 | +3% y/y |
| Chamberlain total students · Chamberlain · Q3-2026 | 40,767 | +1% y/y |
| Walden total students · Walden · Q3-2026 | 54,474 | +12% y/y |
| Medical and Veterinary total students · Medical and Veterinary · Q3-2026 | 5,344 | +4% y/y |
Guidance
Revenue guidance raised from $1,900M-$1,940M to $1,930M-$1,945M; adj. EPS from $7.80-$8.00 to $7.95-$8.15
Raised FY2026 revenue and adjusted EPS guidance due to strong enrollment growth and execution.
Risks flagged
Margin pressure from investment in growth and new campuses
“Adjusted EBITDA margin declined from 27.4% to 26.3% YoY.”
Dependence on regulatory approvals for new campuses
“Two new campuses received full regulatory approval; others pending.”
Competition in healthcare education market
“CEO mentions need for more healthcare professionals; competitive landscape.”
7 May 202610-QTotal revenue $487M (+4% y/y); Net income $42M (-32% y/y); Diluted earnings per share $1.20 (-24% y/y)open
Figures in the filing · each found in the filing text
| Total revenue · Q3-2026 | $487M | +5% y/y |
| Net income · Q3-2026 | $42M | -32% y/y |
| Diluted earnings per share · Q3-2026 | $1.20 | -25% y/y |
| Adjusted net income · Q3-2026 | $69M | -6% y/y |
| Adjusted earnings per share · Q3-2026 | $1.98 | +3% y/y |
| Adjusted operating income · Q3-2026 | $102M | -3% y/y |
| Adjusted operating margin · Q3-2026 | 21.0% | |
| Interest expense · Q3-2026 | $14M | +4% y/y |
| Effective tax rate · Q3-2026 | 25.6% |
Risks flagged
Revenue timing shift
“Walden revenue for the third quarter of fiscal year 2026 was impacted by a shift of one academic week from the third quarter to the second quarter, which resulted in $18.0 million of revenue being recognized during the second quarter of fiscal year 2026.” · word for word
Discontinued operations losses
“We had a loss from discontinued operations of $16.3 million and $15.4 million in the third quarter and first nine months of fiscal year 2026” · word for word
Regulatory dependency
“Changes to financial aid programs that restrict student eligibility or reduce funding levels could have a material adverse effect on Covista’s business, financial condition, results of operations, and cash flows.” · word for word
9 Apr 20268-K · 7.01Enrollment 120,000; Guidance: Revenue CAGR 7-10%, Adj. EPS CAGR 10-14%, enrollment >120,000 by FY2029open
Figures in the filing · each found in the filing text
| Enrollment · FY2029 | 120,000 |
Guidance
Revenue CAGR 7-10%, Adj. EPS CAGR 10-14%, enrollment >120,000 by FY2029
Long-term targets imply confidence in growth and margin expansion; demand driven by healthcare workforce crisis.
Risks flagged
Execution risk on long-term targets; reliance on healthcare workforce demand and partnership success.
“Forward-looking statements subject to risks; targets are aspirational.”
28 Jan 202610-QAdtalem reported Q2 FY2026 revenue of $503.4M (+12.4% YoY) and adjusted EPS of $2.43 (+34.3% YoY), with strong Walden segment growth offset by Chamberlain enrollment decline and regulatory headwinds from OBBBA.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $503M | +12% y/y |
| Net Income · Q2-2026 | $76M | +1% y/y |
| Adjusted EPS · Q2-2026 | $2.43 | +34% y/y |
| Medical and Veterinary Student Enrollment (Sept 2025) · Medical and Veterinary · Sep-2025 | 5,297 | +2% y/y |
| Adjusted Operating Income · Q2-2026 | $126M | +24% y/y |
| Adjusted Operating Margin · Q2-2026 | 25.0% |
Risks flagged
Federal Student Aid Policy Risk
“OBBBA makes several substantial changes to the availability of federal student aid, which many of our students rely on to fund their education, including: ... eventually phasing out the Grad PLUS loan program ... establishing new aggregate federal loan caps ... These changes could have a material adverse effect on our business, financial condition, cash flow” · word for word
Enrollment Decline at Chamberlain
“For the November 2025 session, total student enrollment at Chamberlain decreased 1.0% compared to the same session last year.” · word for word
Increased Operating Costs
“Cost of educational services increased 10.1% ... driven by an increase in labor and other costs to support increased enrollment.” · word for word
28 Jan 20268-K · 2.02Revenue $503M (+12% y/y); Total student enrollment 97,010 (+6% y/y); Adjusted EBITDA $155M (+24% y/y); Guidance: Adjusted EPS guidance raised to $7.80-$8.00 from prior range (not explicitly stated but implied by raise).earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $503M | +12% y/y |
| Total student enrollment · Q2-2026 | 97,010 | +6% y/y |
| Adjusted EBITDA · Q2-2026 | $155M | +24% y/y |
| Adjusted EPS · Q2-2026 | $2.43 | +34% y/y |
| GAAP Net income · Q2-2026 | $76M | +1% y/y |
| Diluted EPS · Q2-2026 | $2.11 | +7% y/y |
| Share repurchases · Q2-2026 | $165M | |
| Net leverage · Q2-2026 | $0.90 |
Guidance
Adjusted EPS guidance raised to $7.80-$8.00 from prior range (not explicitly stated but implied by raise).
Raised FY2026 adjusted EPS guidance; strong Q2 results with double-digit revenue and enrollment growth; margin expansion; active share repurchases.
Risks flagged
Dependence on enrollment growth sustainability; any slowdown could impact revenue and margins.
“Enrollment growth is key driver; tenth consecutive quarter of growth but competitive and demographic risks exist.”
Regulatory and accreditation risks in healthcare education sector.
“Company operates in regulated higher education and healthcare training environment.”
15 Dec 20258-K · 8.01Share repurchase authorization $750M; Prior share repurchase program completed $150Mopen
Figures in the filing · each found in the filing text
| Share repurchase authorization · 2025-12-15 | $750M | |
| Prior share repurchase program completed · 2025-12-15 | $150M |
30 Oct 20258-K · 2.02Total student enrollment 97,359 (+8% y/y); Revenue $462M (+11% y/y); Diluted earnings per share $1.67; Guidance: FY2026 revenue $1,900M-$1,940M; adjusted EPS $7.60-$7.90earningsopen
Figures in the filing · each found in the filing text
| Total student enrollment · Q1-2026 | 97,359 | +8% y/y |
| Revenue · Q1-2026 | $462M | +11% y/y |
| Diluted earnings per share · Q1-2026 | $1.67 | |
| Adjusted EPS · Q1-2026 | $1.75 | +36% y/y |
| Adjusted EBITDA · Q1-2026 | $112M | +16% y/y |
| Adjusted EBITDA margin · Q1-2026 | 24.2% | |
| Net income (GAAP) · Q1-2026 | $62M | |
| Chamberlain enrollment · Chamberlain · Q1-2026 | 39,846 | +2% y/y |
| Walden enrollment · Walden · Q1-2026 | 52,216 | +14% y/y |
| Medical & Veterinary enrollment · Medical and Veterinary · Q1-2026 | 5,297 | +2% y/y |
Guidance
FY2026 revenue $1,900M-$1,940M; adjusted EPS $7.60-$7.90
Guidance maintained with strong Q1 beat; management confident in full-year outlook; Investor Day planned.
Risks flagged
No material risks highlighted; strong enrollment growth and low leverage mitigate downside.
“Net leverage 0.6x; strong free cash flow”
30 Oct 202510-QAdtalem reported strong Q1 FY2026 results with revenue up 10.8% YoY, net income up 33.9%, and adjusted operating margin expansion of 130 bps.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $462M | +11% y/y |
| Net income · Q1-2026 | $62M | +34% y/y |
| Diluted earnings per share · Q1-2026 | $1.67 | +42% y/y |
| Adjusted net income · Q1-2026 | $65M | +29% y/y |
| Diluted adjusted earnings per share · Q1-2026 | $1.75 | +36% y/y |
| Revenue - Chamberlain · Chamberlain · Q1-2026 | $179M | +7% y/y |
| Revenue - Walden · Walden · Q1-2026 | $190M | +18% y/y |
| Revenue - Medical and Veterinary · Medical and Veterinary · Q1-2026 | $93M | +6% y/y |
| Adjusted operating income · Q1-2026 | $90M | +19% y/y |
Risks flagged
Federal Student Aid Policy Risk
“These changes could have a material adverse effect on our business, financial condition, cash flows, or results of operations.” · word for word
Regulatory Implementation Uncertainty
“Due to the complexity of OBBBA, including yet to be promulgated implementing regulations (including how to implement the “Do No Harm” provision discussed below) and lack of interpretive guidance, the impact of OBBBA on our institutions and our business is not yet fully known.” · word for word
Covista Inc. — questions
- What did Covista Inc. file recently?
- 16 SEC filings in the last 12 months. Latest: DEF 14A on 2026-10-02 — Proxy statement disclosing executive compensation, a new equity incentive plan, and detailed non-GAAP financial metrics.
Every figure on this page comes from Covista Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.